Skip to main content
SpringerLink
Log in

Overview of lymphoma

  • Chapter
  • First Online:
Management of Lymphomas: A Case-Based Approach

  • 756 Accesses

Abstract

Diseases characterized by non-infectious enlargement of lymph nodes were recognized as lymphosarcoma and psudoleukemia by Virchow and Cohenheim in 1864 and 1865. Around the same time Thomas Hodgkin described clinical histories and post-mortem findings of seven patients with enlarged lymph nodes and splenomelgaly without inflammation where the disease spread to contiguous lymph nodes and his colleague Samuel Wilks called it Hodgkin disease (HD).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lakhtakia R, Burney I. A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma. Sultan Qaboos University Medical J. 2015;15:e317–321.

    Google Scholar 

  2. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin’s disease and with B symptoms. Cancer Res. 1 1993;53:2118–2122.

    Google Scholar 

  3. Kelly JJ, Karcher DS. Lymphoma and peripheral neuropathy: a clinical review. Muscle Nerve. 2005;31:301–313.

    Google Scholar 

  4. Thomas I, Schwartz RA. Cutaneous paraneoplastic syndromes: uncommon presentations. Clin Dermatol. 2005;23:593–600.

    Google Scholar 

  5. Gagliano RG, Costanzi JJ, Beathard GA, Sarles HE, Bell JD. The nephrotic syndrome associated with neoplasia: an unusual paraneoplastic syndrome. Report of a case and review of the literature. Am J Med. 1976;60:1026–1031.

    Google Scholar 

  6. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Hodgkin Lymphoma. https://seer.cancer.gov/statfacts/html/hodg.html. Accessed March 7, 2017.

  7. International Agency for Research on Cancer, World Health Organization. Non-Hodgkin lymphoma. http://eco.iarc.fr/eucan/Cancer.aspx?Cancer=38. Accessed March 7, 2017.

  8. International Agency for Research on Cancer, World Health Organization. Hodgkin lymphoma. http://eco.iarc.fr/eucan/Cancer.aspx?Cancer=37. Accessed March 7, 2017.

  9. Adzersen KH, Friedrich S, Becker N. Are epidemiological data on lymphoma incidence comparable? Results from an application of the coding recommendations of WHO, InterLymph, ENCR and SEER to a cancer registry dataset. J Cancer Res Clin Oncol. 2016;142:167–175.

    Google Scholar 

  10. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29

    Google Scholar 

  11. Evens AM, Winter JS, Gordon LI, et al. Non-Hodgkin Lymphoma. http://www.cancernetwork.com/cancer-management/non-hodgkin-lymphoma. Accessed March 7, 2017.

  12. Roulland S, Kelly RS, Morgado E, et al. t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma. J Clin Oncol. 2014;32:1347–1355.

    Google Scholar 

  13. Dierickx D, Tousseyn T, Gheysens O. How I treat posttransplant lymphoproliferative disorders. Blood. 2015;126:2274–2283.

    Google Scholar 

  14. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1414–1420.

    Google Scholar 

  15. Lakatos PL, Miheller P. Is there an increased risk of lymphoma and malignancies under anti- TNF therapy in IBD? Curr Drug Targets. 2010;11:179–186.

    Google Scholar 

  16. Morales-Sanchez A, Fuentes-Panana EM. Human viruses and cancer. Viruses. 2014;6:4047–4079.

    Google Scholar 

  17. Ali AS, Al-Shraim M, Al-Hakami AM, Jones IM. Epstein-Barr virus: clinical and epidemiological revisits and genetic basis of oncogenesis. Open Virol J. 2015;9:7–28.

    Google Scholar 

  18. Panfil AR, Martinez MP, Ratner L, Green PL. Human T-cell leukemia virus-associated malignancy. Curr Opin Virol. 2016;20:40–46.

    Google Scholar 

  19. Schollkopf C, Melbye M, Munksgaard L, et al. Borrelia infection and risk of non-Hodgkin lymphoma. Blood. 2008;111:5524–5529.

    Google Scholar 

  20. Morgner A, Bayerdorffer E, Neubauer A, Stolte M. Helicobacter pylori associated gastric B cell MALT lymphoma: predictive factors for regression. Gut. 2001;48:290–292.

    Google Scholar 

  21. Collina F, De Chiara A, De Renzo A, De Rosa G, Botti G, Franco R. Chlamydia psittaci in ocular adnexa MALT lymphoma: a possible role in lymphomagenesis and a different geographical distribution. Infect Agent Cancer. 2012;7:8.

    Google Scholar 

  22. Cerhan JR, Berndt SI, Vijai J, et al. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet. 2014;46:1233–1238.

    Google Scholar 

  23. Rappaport H. Tumors of the Heamtopoeitic System. Atlas of Tumor Pathology. Ann Intern Med. 1967;67(3_Part_1):686–687.

    Google Scholar 

  24. Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer. 1974;34:1488–1503.

    Google Scholar 

  25. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292–293.

    Google Scholar 

  26. [no authors listed]. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112–2135.

    Google Scholar 

  27. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392.

    Google Scholar 

  28. Swerdlow SH, Campo E, Harris NL, et al (Eds). WHO Classification of Tumors of Hematopoeitic and Lymphoid Tissues. 4th edn. World Health Organization, France: IARC Press 2008.

    Google Scholar 

  29. Juliusson G, Abrahamsen AF, Cavallin-Stahl E, et al. Management of non-Hodgkin lymphoma in adults in Scandinavia, United Kingdom, and The Netherlands. Report from the European School of Oncology intercity meeting at Huddinge Hospital, 3rd June, 1988. Acta Oncologica; 28:135–140.

    Google Scholar 

  30. Pusey WA. Cases of sarcoma and of Hodgkin’s disease treated by exposures to x-rays-a preliminary report. JAMA. 1902;38:166–169.

    Google Scholar 

  31. Easson EC, Russell MH. Cure of Hodgkin’s disease. Br Med J. 1963;1:1704–1707.

    Google Scholar 

  32. Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg. 1963;105:574–578.

    Google Scholar 

  33. DeVita VT, Jr., Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643–8653.

    Google Scholar 

  34. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.

    Google Scholar 

  35. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–1545.

    Google Scholar 

  36. Chakraverty R, Mackinnon S. Allogeneic transplantation for lymphoma. J Clin Oncol. 2011;29:1855–1863.

    Google Scholar 

  37. Schuster SJ, Neelapu SS, Santos CF, Popa-McKiver MA, McCord AM, Kwak LW. Idiotype vaccination as consolidation therapy: time for integration into standard of care for follicular lymphoma? J Clin Oncol. 2011;29:4845–4846.

    Google Scholar 

  38. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011;29:2787–2794.

    Google Scholar 

  39. Armitage JO, Coiffier B. Activity of interferon-alpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin’s lymphoma. Ann Oncol. 2000;11:359–361.

    Google Scholar 

  40. Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015;33:251–257.

    Google Scholar 

  41. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for lowgrade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol. 2001;39:181–194.

    Google Scholar 

  42. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–1821.

    Google Scholar 

  43. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigenreceptor-transduced T cells. Blood. 2012;119:2709–2720.

    Google Scholar 

  44. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncology. 2016;17:1283–1294.

    Google Scholar 

  45. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol. 2011;8:85–96.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. City of Hope National Medical Center, Duarte, California, USA

    Jasmine Zain & Larry W. Kwak

Authors
  1. Jasmine Zain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Larry W. Kwak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Larry W. Kwak .

Editor information

Editors and Affiliations

  1. City of Hope Hospital, Duarte, California, USA

    Jasmine Zain

  2. Toni Stephenson Lymphoma Center, City of Hope Hospital, Duarte, California, USA

    Larry W. Kwak

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Zain, J., Kwak, L.W. (2017). Overview of lymphoma. In: Zain, J., Kwak, L. (eds) Management of Lymphomas: A Case-Based Approach. Adis, Cham. https://doi.org/10.1007/978-3-319-26827-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26827-9_1

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-26825-5

  • Online ISBN: 978-3-319-26827-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation